Innovent Biologics, Inc.

HKSE 1801.HK

Innovent Biologics, Inc. Net Income Margin for the year ending December 31, 2023: -16.56%

Innovent Biologics, Inc. Net Income Margin is -16.56% for the year ending December 31, 2023, a 65.37% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Innovent Biologics, Inc. Net Income Margin for the year ending December 31, 2022 was -47.83%, a 34.92% change year over year.
Innovent Biologics, Inc. Net Income Margin for the year ending December 31, 2021 was -73.50%, a -182.95% change year over year.
Innovent Biologics, Inc. Net Income Margin for the year ending December 31, 2020 was -25.97%, a 84.69% change year over year.
Innovent Biologics, Inc. Net Income Margin for the year ending December 31, 2019 was -169.62%, a 99.72% change year over year.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

HKSE: 1801.HK

Innovent Biologics, Inc.

CEO	Dr. De-Chao Yu Ph.D.
IPO Date	Oct. 31, 2018
Location	China
Headquarters	168 Dongping Street
Employees	5,263
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.

Key trends

Past 5 years